SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EARNINGS FLASH L impact

Faeth Therapeutics Expects Phase 2 Endometrial Data by Year-End 2026

Faeth Therapeutics said topline Phase 2 PIK-201 endometrial cancer data are anticipated by year-end 2026. Initial PIK-101 breast cancer safety and efficacy data are expected in 2027.

FTH
SquawkNews Desk

Related stories

Thomson Reuters Reports Higher Revenue as Shares Fall on Investment Costs The Spanish-language wire headline says Thomson Reuters revenue increased while its shares fell due to investment costs; it provides no figures or reporting period. M impact | EARNINGS | Nov 03, 2026, 03:40 PM UTC Authum Investment & Infrastructure Reports September-Quarter Revenue of 6.81 Billion Rupees M impact | EARNINGS | Nov 03, 2026, 03:25 PM UTC Authum Investment & Infrastructure Reports ₹4.17 Billion September-Quarter Net Profit L impact | EARNINGS | Nov 03, 2026, 03:24 PM UTC INOX India Q2FY27 Profit Rises 10% to ₹67 Crore Consolidated profit after tax rose 10% year on year to ₹67 crore in the second quarter of FY27, from ₹62 crore a year earlier. Revenue from operations rose to ₹456 crore. M impact | EARNINGS | Nov 03, 2026, 03:22 PM UTC Ferrari lifts forecasts as Luce EV demand stays strong Ferrari raised its forecasts after outperformance and reported strong demand for its Luce electric vehicle. M impact | EARNINGS | Nov 03, 2026, 03:18 PM UTC Goldpac Group Expects FY Revenue to Decline 5%-15% M impact | EARNINGS | Nov 03, 2026, 03:16 PM UTC